IT201600111171A1 - KIT FOR SKIN TREATMENT AND ITS USE - Google Patents
KIT FOR SKIN TREATMENT AND ITS USEInfo
- Publication number
- IT201600111171A1 IT201600111171A1 IT102016000111171A IT201600111171A IT201600111171A1 IT 201600111171 A1 IT201600111171 A1 IT 201600111171A1 IT 102016000111171 A IT102016000111171 A IT 102016000111171A IT 201600111171 A IT201600111171 A IT 201600111171A IT 201600111171 A1 IT201600111171 A1 IT 201600111171A1
- Authority
- IT
- Italy
- Prior art keywords
- cosmetic
- composition
- kit according
- acid
- skin
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 33
- 239000000203 mixture Substances 0.000 claims description 49
- 239000002537 cosmetic Substances 0.000 claims description 34
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 12
- 208000032544 Cicatrix Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 230000037387 scars Effects 0.000 claims description 8
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 229960002510 mandelic acid Drugs 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 6
- 229960004705 kojic acid Drugs 0.000 claims description 6
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 5
- -1 pH regulators Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000037303 wrinkles Effects 0.000 claims description 5
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 229960000448 lactic acid Drugs 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 3
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 241000086254 Arnica montana Species 0.000 claims description 3
- 201000006082 Chickenpox Diseases 0.000 claims description 3
- 206010014970 Ephelides Diseases 0.000 claims description 3
- 208000003351 Melanosis Diseases 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 208000012641 Pigmentation disease Diseases 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 206010039580 Scar Diseases 0.000 claims description 3
- 206010040829 Skin discolouration Diseases 0.000 claims description 3
- 206010040925 Skin striae Diseases 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims description 3
- 208000031439 Striae Distensae Diseases 0.000 claims description 3
- 206010046980 Varicella Diseases 0.000 claims description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229940064972 echinacea angustifolia extract Drugs 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000013020 final formulation Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 208000000069 hyperpigmentation Diseases 0.000 claims description 3
- 230000003810 hyperpigmentation Effects 0.000 claims description 3
- 230000000366 juvenile effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000019612 pigmentation Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 201000003385 seborrheic keratosis Diseases 0.000 claims description 3
- 230000037370 skin discoloration Effects 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000008378 epithelial damage Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 43
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000243251 Hydra Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940002386 calendula officinalis extract Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940061605 tetrasodium glutamate diacetate Drugs 0.000 description 1
- UZVUJVFQFNHRSY-OUTKXMMCSA-J tetrasodium;(2s)-2-[bis(carboxylatomethyl)amino]pentanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@@H](C([O-])=O)N(CC([O-])=O)CC([O-])=O UZVUJVFQFNHRSY-OUTKXMMCSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
“KIT PER IL TRATTAMENTO DELLA PELLE E SUO IMPIEGO” "KIT FOR SKIN TREATMENT AND ITS USE"
DESCRIZIONE DESCRIPTION
CAMPO DELL’INVENZIONE FIELD OF THE INVENTION
L’invenzione concerne un kit e un metodo di applicazione dello stesso per il trattamento della pelle. In particolare, l’invenzione concerne prodotti e metodi di applicazione per il trattamento della cute e di problemi ad essa connessi derivanti da sole, ferite, malattie e patologie della pelle stessa, invecchiamento e stress. STATO DELLA TECNICA The invention concerns a kit and a method of application of the same for the treatment of the skin. In particular, the invention concerns products and application methods for the treatment of the skin and related problems resulting from the sun, wounds, diseases and pathologies of the skin itself, aging and stress. STATE OF THE TECHNIQUE
Nella pratica medica/estetica è noto effettuare trattamenti della pelle per levigare e migliorare l'aspetto della cute. Fin dall’antichità sono state proposte ed impiegate diverse sostanze tra cui zolfo, pomice, polveri minerali, finemente macinati e miscelati a sostanze ed ingredienti di origine vegetale. In medical / aesthetic practice it is known to carry out skin treatments to smooth and improve the appearance of the skin. Since ancient times, various substances have been proposed and used including sulfur, pumice, mineral powders, finely ground and mixed with substances and ingredients of vegetable origin.
In epoca moderna, è nota la pratica del peeling chimico, effettuato in modo ambulatoriale per il trattamento estetico/curativo/riparatore della pelle. Per esempio negli anni ‘70 e ‘80 era noto l'uso dell’acido tricloroacetico, dell'acido salicilico e dell'acido lattico e furono effettuate pubblicazioni per risultati ottenuti nella terapia di numerosi inestetismi e patologie cutanee con l'utilizzo dell'acido glicolico e degli alfa idrossi acidi in generale. In modern times, the practice of chemical peeling is known, carried out on an outpatient basis for the aesthetic / curative / repairing treatment of the skin. For example in the 70s and 80s the use of trichloroacetic acid, salicylic acid and lactic acid was known and publications were made for results obtained in the treatment of numerous skin imperfections and pathologies with the use of acid. glycolic and alpha hydroxy acids in general.
Il peeling chimico attraverso l’impiego di una sostanza chimica sostanzialmente permette una accelerazione della esfoliazione della pelle. Un peeling molto superficiale accelera l'esfoliazione naturale dello strato corneo, mentre un peeling che agisce a livello più profondo crea necrosi e infiammazione nell'epidermide, nel derma papillare o nel derma reticolare. Il peeling chimico pertanto attiva una serie di meccanismi cellulari che portano al trattamento terapeutico estetico voluto della pelle. D’altra parte esso innesca reazioni infiammatorie con attivazione dei mediatori dell'infiammazione che da un lato possono attivare la produzione di nuove fibre di collagene e di glicosaminoglicani, ma dall’altro, agendo a livelli epidermici profondi comportano anche rischi di complicazioni ed esiti indesiderati. E’ pertanto sentita l’esigenza di eseguire trattamenti e terapie che ottengono eccellenti risultati estetico/curativi con il minor rischio possibile. The chemical peeling through the use of a chemical substance essentially allows an acceleration of the exfoliation of the skin. A very superficial peel accelerates the natural exfoliation of the stratum corneum, while a peel that acts at a deeper level creates necrosis and inflammation in the epidermis, papillary dermis or reticular dermis. The chemical peel therefore activates a series of cellular mechanisms that lead to the desired aesthetic therapeutic treatment of the skin. On the other hand, it triggers inflammatory reactions with activation of the inflammatory mediators which on the one hand can activate the production of new collagen fibers and glycosaminoglycans, but on the other hand, acting at deep epidermal levels also entails risks of complications and unwanted outcomes. . The need is therefore felt to perform treatments and therapies that obtain excellent aesthetic / curative results with the lowest possible risk.
E’ noto per esempio che l’acido tricloroacetico in elevata concentrazione raggiunge il derma e può causare denaturazione e precipitazione delle proteine dell’epidermide, dando luogo a sbiancamento con effetto denominato “frost bianco” e alla formazione di uno strato di tessuto alterato con aspetto di una continua “crosta”, la cui guarigione corrisponde alla rigenerazione cutanea desiderata. Tuttavia è evidente che la fase dalla formazione del tessuto con croste fino alla sua guarigione è un periodo temporale nel quale risulta impossibilitata la conduzione di una vita normale, non solo per una problematica estetica, ma anche per il rischio di infezioni a contatto con l’ambiente esterno. For example, it is known that trichloroacetic acid in high concentration reaches the dermis and can cause denaturation and precipitation of epidermal proteins, giving rise to whitening with an effect called "white frost" and the formation of a layer of altered tissue with an appearance of a continuous "crust", the healing of which corresponds to the desired skin regeneration. However, it is evident that the phase from the formation of the crusted tissue to its healing is a period of time in which it is impossible to lead a normal life, not only for an aesthetic problem, but also for the risk of infections in contact with the external environment.
Nel documento EP1979053 viene descritto un prodotto ed un procedimento per prepararlo che comprende le fasi di rendere disponibile una adatta quantità di acido tricloroacetico, di perossido di idrogeno e di un composto basico tamponante per preparare un prodotto per il trattamento della pelle. Come indicato in descrizione, il prodotto presenta caratteristiche di peeling dovuta alla azione concomitante dell’acido tricloroacetico e del perossido di idrogeno e trova applicazione anche come medicamento per il trattamento di patologie della pelle. Scopo della presente invenzione è fornire prodotti peeling per il trattamento ella pelle che abbiano buoni risultati estetico/curativo, e che contemporaneamente non solo non danneggino la pelle, minimizzando al massimo i rischi connessi al trattamento, ma anche permettano una conduzione normale della vita durante il trattamento stesso. Document EP1979053 discloses a product and a process for preparing it which comprises the steps of making available a suitable amount of trichloroacetic acid, hydrogen peroxide and a basic buffering compound to prepare a product for the treatment of the skin. As indicated in the description, the product has peeling characteristics due to the concomitant action of trichloroacetic acid and hydrogen peroxide and is also used as a medicament for the treatment of skin diseases. The purpose of the present invention is to provide peeling products for the treatment of the skin which have good aesthetic / curative results, and which at the same time not only do not damage the skin, minimizing the risks associated with the treatment, but also allow a normal life conduction during the treatment. treatment itself.
SOMMARIO SUMMARY
Gli inventori della presente invenzione hanno sorprendentemente scoperto che il trattamento con una particolare composizione di acidi per peeling, comprendente almeno l’acido tricloroacetico, raggiugeva lo scopo dell’invenzione se associato ad un trattamento a base di ozono. The inventors of the present invention have surprisingly discovered that the treatment with a particular composition of acids for peeling, including at least trichloroacetic acid, achieved the purpose of the invention when associated with an ozone-based treatment.
Pertanto l’invenzione consiste in un kit cosmetico comprendente: Therefore the invention consists of a cosmetic kit comprising:
a) un prodotto ozonizzato, a) an ozonated product,
b) una composizione cosmetica comprendente acido tricloroacetico. b) a cosmetic composition comprising trichloroacetic acid.
Preferibilmente la composizione cosmetica b) comprende altresì almeno un ulteriore acido scelto dal gruppo consistente in acido lattico, acido citrico, acido cogico e acido mandelico. Preferably, the cosmetic composition b) also comprises at least one further acid selected from the group consisting of lactic acid, citric acid, kojic acid and mandelic acid.
Il kit cosmetico dell’invenzione è per l’uso in modo sequenziale, ossia prima il prodotto a) e poi la composizione b), preferibilmente secondo il foglietto illustrativo in esso contenuto. The cosmetic kit of the invention is for use sequentially, i.e. first the product a) and then the composition b), preferably according to the package insert contained therein.
In un ulteriore aspetto l’invenzione concerne il kit per l’uso nel trattamento della pelle. In a further aspect, the invention concerns the kit for use in the treatment of the skin.
Sotto ancora un ulteriore aspetto, viene fornito un kit per l’uso nel trattamento della pelle, in cui il trattamento delle pelle comprende il trattamento di una patologia delle pelle scelta dal gruppo consistente in cheratosi seborroiche, acne, acne giovanile, cicatrici da acne, cicatrici da varicella, cicatrici post-operatorie, lentiggini solari, discromie cutanee, lesioni precancerose, pigmentazione alterata, rughe, smagliature, danni epiteliali da sole, macchie della pelle, iperpigmentazioni e rosacea. In yet another aspect, a kit is provided for use in skin treatment, where the skin treatment includes the treatment of a skin condition chosen from the group consisting of seborrheic keratoses, acne, juvenile acne, acne scars, chickenpox scars, post-operative scars, solar freckles, skin discolorations, precancerous lesions, altered pigmentation, wrinkles, stretch marks, sun damage, skin spots, hyperpigmentation and rosacea.
DESCRIZIONE DETTAGLIATA DELL’INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
L’invenzione pertanto concerne un kit cosmetico comprendente: The invention therefore concerns a cosmetic kit comprising:
a) un prodotto ozonizzato, a) an ozonated product,
b) una composizione cosmetica comprendente acido tricloroacetico. b) a cosmetic composition comprising trichloroacetic acid.
Il prodotto ozonizzato a) dell’invenzione è preferibilmente un prodotto cosmetico ozonizzato, quale un olio o più olii ozonizzati sotto forma di crema o gelo, preferibilmente esso è un prodotto ozonizzato in forma di gel. Qualora sotto forma di olio ozonizzato, detto olio comprende da 3 a 98% di ozono, preferibilmente olio ozonizzato con contenuto di ozono di almeno 80%. Nella forma preferita dell’invenzione il prodotto è un olio di semi di girasole ozonizzato sotto forma di un gelo, preferibilmente comprendente olio di semi di girasole ozonizzato al 98%, comprendente altresì eccipienti per la sua formulazione finale. The ozonated product a) of the invention is preferably an ozonated cosmetic product, such as an oil or more ozonated oils in the form of cream or ice, preferably it is an ozonated product in the form of a gel. If in the form of ozonated oil, said oil comprises from 3 to 98% ozone, preferably ozonated oil with an ozone content of at least 80%. In the preferred form of the invention, the product is an ozonated sunflower oil in the form of a frost, preferably comprising 98% ozonated sunflower oil, also comprising excipients for its final formulation.
La composizione cosmetica per peeling b) dell’invenzione comprende acido tricloroacetico. The cosmetic composition for peeling b) of the invention includes trichloroacetic acid.
L’acido tricloroacetico è preferibilmente compreso nella composizione cosmetica b) in una quantità da 5 a 50% in peso rispetto al peso finale della composizione. Più preferibilmente l’acido tricloroacetico è presente nella composizione b) nell’intervallo da 15 a 30%, ancor più preferibilmente esso è in quantità del 20% in peso rispetto al peso della composizione. Trichloroacetic acid is preferably included in the cosmetic composition b) in an amount from 5 to 50% by weight with respect to the final weight of the composition. More preferably, trichloroacetic acid is present in composition b) in the range from 15 to 30%, even more preferably it is in an amount of 20% by weight with respect to the weight of the composition.
Preferibilmente la composizione cosmetica b) comprende altresì almeno un ulteriore acido scelto dal gruppo consistente in acido lattico, acido citrico, acido cogico e acido mandelico. Preferably, the cosmetic composition b) also comprises at least one further acid selected from the group consisting of lactic acid, citric acid, kojic acid and mandelic acid.
Preferibilmente l’acido mandelico è presente nella composizione b) in una percentuale in peso da 0.1% a 50% rispetto al preso finale della composizione b). Preferibilmente l’acido lattico è presente nella composizione b) in una percentuale in peso da 0.1% a 50% rispetto al preso finale della composizione b). Preferably mandelic acid is present in composition b) in a weight percentage from 0.1% to 50% with respect to the final strength of composition b). Preferably, lactic acid is present in composition b) in a weight percentage from 0.1% to 50% with respect to the final strength of composition b).
Preferibilmente l’acido citrico è presente nella composizione b) in una percentuale in peso da 0.1% a 50% rispetto al preso finale della composizione b). Citric acid is preferably present in composition b) in a weight percentage from 0.1% to 50% with respect to the final amount of composition b).
Preferibilmente l’acido cogico è presente nella composizione b) in una percentuale in peso da 0.1% a 50% rispetto al preso finale della composizione b). Preferably kojic acid is present in composition b) in a weight percentage from 0.1% to 50% with respect to the final strength of composition b).
Preferibilmente l’acido mandelico è presente nella composizione b) in una percentuale in peso da 0.1% a 50% rispetto al preso finale della composizione b). Preferibilmente la composizione b) dell’invenzione è sotto forma di gelo. Preferably mandelic acid is present in composition b) in a weight percentage from 0.1% to 50% with respect to the final strength of composition b). Preferably the composition b) of the invention is in the form of frost.
In una forma preferita dell’invenzione la composizione b) comprende altresì almeno una sostanza di origine vegetale scelta dal gruppo consistente in arnica montana, estratto di Calendula Officinalis e estratto di Echinacea Angustifolia. La composizione b) dell’invenzione può comprendere altresì eccipienti adatti alla sua formulazione finale, quali, ad esempio, gelificanti, veicolanti, tamponi, regolatori di pH, conservanti, sostanze antibatteriche, idratanti, umettanti, esfolianti, emulsionanti e chelanti. In a preferred form of the invention, composition b) also comprises at least one substance of vegetable origin selected from the group consisting of mountain arnica, Calendula Officinalis extract and Echinacea Angustifolia extract. Composition b) of the invention may also include excipients suitable for its final formulation, such as, for example, gelling agents, carriers, buffers, pH regulators, preservatives, antibacterial substances, moisturizers, humectants, exfoliants, emulsifiers and chelators.
Sotto un altro aspetto, il kit cosmetico dell’invenzione è per l’uso in modo sequenziale, ossia del prodotto a) e successivamente della composizione b), preferibilmente secondo il foglietto illustrativo in esso contenuto. From another aspect, the cosmetic kit of the invention is for use in a sequential manner, that is, of the product a) and subsequently of the composition b), preferably according to the package insert contained therein.
In un ulteriore aspetto l’invenzione concerne il kit per l’uso cosmetico nel trattamento della pelle. Il kit dell’invenzione viene quindi applicato sulla pelle, preferibilmente in modo sequenziale ossia, prima il prodotto ozonizzato a) e successivamente la composizione b) di acidi. In a further aspect, the invention concerns the kit for cosmetic use in the treatment of the skin. The kit of the invention is then applied to the skin, preferably sequentially, that is, first the ozonated product a) and then the composition b) of acids.
Dopo l’applicazione del prodotto a) e della composizione b) sulla parte da trattare il prodotto può essere eliminato, per esempio con abbondante acqua. After applying the product a) and composition b) on the part to be treated, the product can be eliminated, for example with plenty of water.
Senza esser legati ad alcuna teoria, gli inventori della presente invenzione ritengono che il kit abbia raggiunto gli scopi suddetti, ossia fornire un prodotto peeling per il trattamento della pelle che abbia buoni risultati estetico/curativo, e che contemporaneamente non solo non danneggi la pelle, minimizzando al massimo i rischi connessi al trattamento, ma anche permetta una conduzione normale della vita durante il trattamento stesso, proprio mediante l’impiego del prodotto ozonizzato, il quale favorisce la permeabilità cutanea della composizione b) dell’invenzione, permettendo così un uso di acidi in quantità inferiore e diminuendo di conseguenza l’impatto sulla pelle. Without being bound to any theory, the inventors of the present invention believe that the kit has achieved the aforementioned purposes, namely to provide a peeling product for the treatment of the skin which has good aesthetic / curative results, and which at the same time not only does not damage the skin, minimizing the risks associated with the treatment, but also allowing a normal conduction of life during the treatment itself, precisely through the use of the ozonated product, which favors the skin permeability of the composition b) of the invention, thus allowing the use of acids in lower quantities and consequently decreasing the impact on the skin.
Vantaggiosamente, in caso di pelli difficili da trattare quali pelli ispessite, molto rugose, macchiate o danneggiate, il kit dell’invenzione può prevedere una seconda applicazione del prodotto ozonizzato a) successivamente dopo la sequenza di applicazione prodotto ozonizzato a) - composizione b). Advantageously, in the case of difficult to treat leathers such as thickened, very wrinkled, stained or damaged leathers, the kit of the invention can provide for a second application of the ozonated product a) subsequently after the ozonated product application sequence a) - composition b).
In una ulteriore forma vantaggiosa del kit dell’invenzione, esso comprende altresì una crema c) idratante e lenitiva da applicare dopo avere eliminato il prodotto b), ossia in modo sequenziale successivo alla composizione b). In ulteriore aspetto pertanto il kit dell’invenzione può comprendere quindi un prodotto c) cremoso, preferibilmente a base di acido ialuronico e/o alfa-bisabololo. In a further advantageous form of the kit of the invention, it also comprises a moisturizing and soothing cream c) to be applied after eliminating the product b), i.e. sequentially subsequent to composition b). In a further aspect, therefore, the kit of the invention can therefore comprise a creamy product c), preferably based on hyaluronic acid and / or alpha-bisabolol.
Il Kit dell’invenzione può essere applicato per più applicazioni distanziate preferibilmente di 7-15 giorni, permettendo di ottenere risultati visibili fin dalla prima applicazione come sarà evidente nella parte sperimentale. The kit of the invention can be applied for multiple applications preferably 7-15 days apart, allowing to obtain visible results from the first application as will be evident in the experimental part.
In un ulteriore aspetto l’invenzione concerne il kit per l’uso cosmetico nel trattamento di una patologia delle pelle scelta dal gruppo consistente in cheratosi seborroiche, acne, acne giovanile, cicatrici da acne, cicatrici da varicella, cicatrici post-operatorie, lentiggini solari, discromie cutanee, lesioni precancerose, pigmentazione alterata, rughe, smagliature, danni epiteliali da sole, macchie della pelle, iperpigmentazioni, rosacea. In a further aspect, the invention relates to the kit for cosmetic use in the treatment of a skin pathology chosen from the group consisting of seborrheic keratoses, acne, juvenile acne, acne scars, chicken pox scars, post-operative scars, solar freckles. , skin discoloration, precancerous lesions, altered pigmentation, wrinkles, stretch marks, epithelial damage from the sun, skin spots, hyperpigmentation, rosacea.
Sorprendentemente il kit dell’invenzione corrisponde ad un peeling cosmetico ideale per il trattamento cosmetico delle patologie indicate più sopra, migliorando contemporaneamente tonicità, elasticità della cute e restituendo un aspetto giovanile, lucentezza e levigatezza alla cute. Surprisingly, the kit of the invention corresponds to an ideal cosmetic peeling for the cosmetic treatment of the aforementioned diseases, simultaneously improving tone, elasticity of the skin and restoring a youthful appearance, shine and smoothness to the skin.
Le proprietà vantaggiose del procedimento dell’invenzione sono altresì supportate dalla parte sperimentale che segue. The advantageous properties of the process of the invention are also supported by the experimental part that follows.
Parte sperimentale Experimental part
Esempio 1: Preparazione del kit dell’invenzione Example 1: Preparation of the invention kit
E’ stato fornito un prodotto a) di gel ozonizzato venduto con nome commerciale UC 3582-100 da Uras Cosmetici da 100 ml avente la seguente composizione: acqua, glicerina, olio di semi di girasole ozonizzato al 98% propilene glicole, propandiolo, carbomer, arginina, gomma di xantano, fenossietanolo, o-cimen-5-olo, te-tetraiodato, etilesilglicerina. A 100 ml ozonated gel product sold under trade name UC 3582-100 was supplied with the following composition: water, glycerin, ozonated sunflower oil 98% propylene glycol, propanediol, carbomer, arginine, xanthan gum, phenoxyethanol, o-cimen-5-ol, te-tetraiodate, ethylhexylglycerin.
E’ stata preparata una composizione b) comprendente come ingredienti: A composition b) was prepared comprising as ingredients:
- acqua deionizzata doppia osmosi inversa (81.9999% in peso) - double reverse osmosis deionized water (81.9999% by weight)
- acido tricloroacetico (20.0000% in peso), - trichloroacetic acid (20.0000% by weight),
- acido lattico (0.10% peso) - lactic acid (0.10% weight)
- acido cogico (1.0000% peso) - kojic acid (1.0000% weight)
- acido citrico (0.1000% peso) - citric acid (0.1000% weight)
- acido mandelico (0.4000% peso) - mandelic acid (0.4000% weight)
- gelificante: gomma di xantano (1.8000% in peso); - gelling agent: xanthan gum (1.8000% by weight);
- veicolante: etossidiglicole (0.5000% in peso); - carrier: ethoxyglycol (0.5000% by weight);
- regolatore pH, tampone: sodio idrossido (1.0000% in peso); - pH regulator, buffer: sodium hydroxide (1.0000% by weight);
- conservante, antibatterico: fenetilalcool (0.4060% in peso); - preservative, antibacterial: phenethyl alcohol (0.4060% by weight);
- idratante, conservante: caprilil glicole (0.2940% in peso); - moisturizer, preservative: caprylyl glycol (0.2940% by weight);
- veicolante, umettante: propilene glicole (0.1941% in peso); - carrier, humectant: propylene glycol (0.1941% by weight);
- emulsionante, regolatore di pH: trietanolamina (0.1000% in peso) - emulsifier, pH regulator: triethanolamine (0.1000% by weight)
- chelante: acido fitico (0.0500% in peso); - chelator: phytic acid (0.0500% by weight);
- sostanza di origine vegetale: arnica montana (0. 0294% in peso) con azione antiecchimotica, revulsiva, iperemizzante, lenitiva e anticongestionante; - substance of vegetable origin: mountain arnica (0. 0294% by weight) with anti-ecchymotic, revulsive, hyperemic, soothing and anticongestant action;
- sostanza di origine vegetale: estratto di calendula officinalis (0. 0200% in peso) avente attività antiflogistica, riepitelizzante, di accelerazione del turn over epidermico e di promozione dei fibroblasti del derma per favorire la sintesi del collagene; - substance of vegetable origin: calendula officinalis extract (0.0200% by weight) with anti-inflammatory, re-epithelizing, acceleration of epidermal turnover and promotion of dermal fibroblasts to promote collagen synthesis;
- sostanza di origine vegetale: estratto Echinacea Angustifolia (0.0100% in peso) avente marcata attività antialuronidasina e immunostimolante, riepitelizzante, rassodante, rigenerante e elasticizzante; - substance of vegetable origin: Echinacea Angustifolia extract (0.0100% by weight) with marked antialuronidasina and immunostimulating, restorative, firming, regenerating and elasticising activity;
- conservante: fenossietanolo (0.0009% in peso), etilesilglicerina (0.0001% in peso); - preservative: phenoxyethanol (0.0009% by weight), ethylhexylglycerin (0.0001% by weight);
- chelante: tetrasodio glutammato diacetato (0.0001% in peso). - chelator: tetrasodium glutamate diacetate (0.0001% by weight).
Gli ingredienti sono stati quindi miscelati e si è ottenuta la composizione b). The ingredients were then mixed and composition b) was obtained.
Esempio 2: Example 2:
Trattamento della pelle con il kit dell’invenzione Skin treatment with the kit of the invention
Il soggetto a cui si intendeva applicare il kit dell’invenzione come peeling è stato adeguatamente preparato ed informato sul fatto che avrebbe percepito un leggero bruciore-pizzicore alla applicazione del prodotto ionizzato indicato all’esempio 1. Il prodotto gel ionizzato è stato quindi applicato nella zona della pelle di interesse e lasciato in posa per 5 minuti. Dopo risciacquo è stata applicata la composizione b) indicata nell’esempio 1 nella zona della pelle interessata dal trattamento. La composizione, che era sotto forma di gel, è stata quindi applicata con massaggio utilizzando guanti di vinile o nitrile per circa 5 minuti o più, ossia fino a quando è stato possibile effettuare un pumping per l’adesività della parte di cute trattata. Questo permetteva una ottima diffusione del prodotto e di riattivare la circolazione superficiale. Il numero di applicazioni veniva giudicato sulla base dell’effetto desiderato. La composizione veniva così poi eliminata con abbondante acqua. Il kit dell’invenzione è stato anche applicato su soggetti con pelle ispessita, molto rugosa e macchiata. In questo caso prima di rimuovere la composizione b) è stata riapplicata una quantità ulteriore del prodotto a) ionizzato, massaggiando per circa 2-3 minuti, prima di eliminare completamente la composizione. The subject to whom it was intended to apply the kit of the invention as a peeling was adequately prepared and informed that he would have perceived a slight stinging-itch when applying the ionized product indicated in example 1. The ionized gel product was then applied in the area of the skin of interest and left on for 5 minutes. After rinsing, composition b) indicated in example 1 was applied to the area of the skin affected by the treatment. The composition, which was in the form of a gel, was then applied with a massage using vinyl or nitrile gloves for about 5 minutes or more, that is, until it was possible to pump for the adhesiveness of the treated skin. This allowed an excellent diffusion of the product and to reactivate the superficial circulation. The number of applications was judged on the basis of the desired effect. The composition was thus then eliminated with abundant water. The invention kit was also applied to subjects with thickened, very wrinkled and stained skin. In this case, before removing the composition b) a further quantity of the ionized product a) was reapplied, massaging for about 2-3 minutes, before completely eliminating the composition.
Dopo la rimozione completa dei prodotti dell’invenzione con abbondante acqua, vantaggiosamente veniva applicata una crema lenitiva idratante. I soggetti furono quindi trattati sulla parte di cute interessata dal peeling e asciutta con uno strato uniforme di una crema a base di acido ialuronico e alfa-bisabololo, venduta da Uras Cosmetici come Hydra Mask e Hydra Cream. After the complete removal of the products of the invention with plenty of water, a soothing moisturizing cream was advantageously applied. The subjects were then treated on the part of the skin affected by the peeling and dry with a uniform layer of a cream based on hyaluronic acid and alpha-bisabolol, sold by Uras Cosmetici as Hydra Mask and Hydra Cream.
Esempio 3: valutazione dei risultati del peeling effettuato con il kit dell’invenzione E’ stato condotto un test con 107 soggetti di età compresa fra i 30 e i 67 anni. I soggetti sono stati trattati ambulatorialmente sotto la supervisione di un medico estetico con il kit dell’esempio 1, seguendo la modalità di applicazione indicata nell’esempio 2, per una applicazione o per tre applicazioni effettuate l’una a distanza di 10 giorni dall’altra. Example 3: evaluation of the results of the peeling carried out with the kit of the invention A test was conducted with 107 subjects aged between 30 and 67 years. The subjects were treated on an outpatient basis under the supervision of an aesthetic doctor with the kit of example 1, following the method of application indicated in example 2, for one application or for three applications each carried out 10 days after other.
I soggetti sono quindi stati valutati immediatamente dopo una singola applicazione o tre applicazioni. The subjects were then evaluated immediately after a single application or three applications.
Sono stati ottenuti i seguenti risultati, espressi come percentuale sulla totalità dei soggetti trattati: The following results were obtained, expressed as a percentage of the totality of treated subjects:
Dopo 1 applicazione: After 1 application:
il 99% dei soggetti presentava la pelle morbida e distesa; 99% of subjects had soft and relaxed skin;
il 94% dei soggetti presentava la pelle rivitalizzata, riparata e illuminata; 94% of subjects had revitalized, repaired and brightened skin;
l’87% presentava ridotta presenza di rughe, segni di età e cicatrici; 87% had reduced presence of wrinkles, signs of age and scars;
l’89% presentava la pelle più giovane; 89% had younger skin;
il 77% presentava una pelle rassodata e di migliorata compattezza; 77% had a firmer skin and improved firmness;
l’84% presentava migliorata tonicità e grana delle pelle; 84% had improved skin tone and texture;
l’89% presentava macchie notevolmente schiarite. 89% had noticeably lightened spots.
Dopo 3 applicazioni: After 3 applications:
il 99% dei soggetti presentava la pelle morbida e distesa; 99% of subjects had soft and relaxed skin;
il 97% dei soggetti presentava la pelle rivitalizzata, riparata e illuminata; 97% of the subjects had revitalized, repaired and brightened skin;
il 94% presentava ridotta presenza di rughe, segni di età e cicatrici; 94% had reduced presence of wrinkles, signs of age and scars;
il 98% presentava la pelle più giovane; 98% had younger skin;
il 91% presentava una pelle rassodata e di migliorata compattezza; 91% had firmer skin and improved firmness;
il 93% presentava migliorata tonicità e grana delle pelle; 93% had improved skin tone and texture;
il 94% presentava macchie notevolmente schiarite. 94% had markedly lightened spots.
Sia nel caso di una applicazione che nel caso di tre applicazioni successive, i soggetti trattati non presentavano effetti negativi estetici evidenti di arrossamenti o croste da impedire la normale conduzione della vita subito dopo l’applicazione del trattamento effettuato con il kit dell’invenzione. Both in the case of one application and in the case of three subsequent applications, the treated subjects did not have any evident negative aesthetic effects of redness or scabs that would prevent the normal conduction of life immediately after the application of the treatment carried out with the kit of the invention.
Claims (14)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000111171A IT201600111171A1 (en) | 2016-11-04 | 2016-11-04 | KIT FOR SKIN TREATMENT AND ITS USE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000111171A IT201600111171A1 (en) | 2016-11-04 | 2016-11-04 | KIT FOR SKIN TREATMENT AND ITS USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201600111171A1 true IT201600111171A1 (en) | 2018-05-04 |
Family
ID=58228405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102016000111171A IT201600111171A1 (en) | 2016-11-04 | 2016-11-04 | KIT FOR SKIN TREATMENT AND ITS USE |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT201600111171A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2431581A (en) * | 2005-10-27 | 2007-05-02 | Steven Karim | Ozonated oil formulations |
| WO2008056389A1 (en) * | 2006-11-06 | 2008-05-15 | Istituto Fitofarmaceutico Euganeo S.R.L. | Drug based on free ozonized oleic acid, process for its preparation, and use of the drug |
| WO2008056388A1 (en) * | 2006-11-06 | 2008-05-15 | Istituto Fitofarmaceutico Euganeo S.R.L. | Drug based on ozonized terpenes or terpene-derivatives, processes for producing it and uses thereof |
| JP2008231010A (en) * | 2007-03-20 | 2008-10-02 | Shiseido Co Ltd | External preparation for skin |
| US20090110646A1 (en) * | 2005-12-13 | 2009-04-30 | Rossana Castellana | Product for Treating the Skin and Mucous Membranes, and Relative Method of Preparation |
| US20090196926A1 (en) * | 2005-01-24 | 2009-08-06 | Mbs S.R.L | Nano-structured thixotropic inorganic peeling gels |
| WO2012120454A1 (en) * | 2011-03-07 | 2012-09-13 | Neovalis S.R.L. | Composition for topical use based on ozonized oil |
| EP3006016A1 (en) * | 2014-10-06 | 2016-04-13 | Medical Brands Research B.V. | Dermatological kit comprising compositions based on Hibiscus flower and Buriti oil |
-
2016
- 2016-11-04 IT IT102016000111171A patent/IT201600111171A1/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090196926A1 (en) * | 2005-01-24 | 2009-08-06 | Mbs S.R.L | Nano-structured thixotropic inorganic peeling gels |
| GB2431581A (en) * | 2005-10-27 | 2007-05-02 | Steven Karim | Ozonated oil formulations |
| US20090110646A1 (en) * | 2005-12-13 | 2009-04-30 | Rossana Castellana | Product for Treating the Skin and Mucous Membranes, and Relative Method of Preparation |
| WO2008056389A1 (en) * | 2006-11-06 | 2008-05-15 | Istituto Fitofarmaceutico Euganeo S.R.L. | Drug based on free ozonized oleic acid, process for its preparation, and use of the drug |
| WO2008056388A1 (en) * | 2006-11-06 | 2008-05-15 | Istituto Fitofarmaceutico Euganeo S.R.L. | Drug based on ozonized terpenes or terpene-derivatives, processes for producing it and uses thereof |
| JP2008231010A (en) * | 2007-03-20 | 2008-10-02 | Shiseido Co Ltd | External preparation for skin |
| WO2012120454A1 (en) * | 2011-03-07 | 2012-09-13 | Neovalis S.R.L. | Composition for topical use based on ozonized oil |
| EP3006016A1 (en) * | 2014-10-06 | 2016-04-13 | Medical Brands Research B.V. | Dermatological kit comprising compositions based on Hibiscus flower and Buriti oil |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE GNPD [online] MINTEL; 1 February 2014 (2014-02-01), PETER THOMAS ROTH: "40% Triple Acid Peel", XP002771421, Database accession no. 2276907 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2549534T3 (en) | Use of a natural agent in cosmetic compositions | |
| CN104856892A (en) | Cosmetic or skin care product preparation rich in growth factors and preparation method therefor | |
| ES2856480T3 (en) | Cosmetic uses of swertiamarin | |
| CN109937031A (en) | Kangaroo pawl extract for beautifying use | |
| TW201109039A (en) | Cosmetic uses of modified stressed yeast extracts and related compositions | |
| RU2755201C1 (en) | Skincare tonic | |
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| JP2016510016A (en) | Cosmetic composition containing brown algae extract, yeast extract and ascorbic acid | |
| WO2017100873A1 (en) | Cosmetic composition and use thereof | |
| CN111991336B (en) | Multi-effect gel essence and preparation method and application thereof | |
| ITMI20111806A1 (en) | COMPOSITION FOR THE TREATMENT OF SKIN LESIONS | |
| BRPI0504797B1 (en) | topical formulation, cosmetic treatment method for skin rejuvenation, cosmetic treatment method and use of a formulation | |
| US20070202061A1 (en) | Cosmetic skincare applications employing mineral-derived tubules for controlled release | |
| CN104473860B (en) | Ganodermalucidumcollagen mask and preparation process thereof | |
| CN106562904A (en) | Facial mask containing passion fruit extract and preparation method of facial mask | |
| TW201424765A (en) | Collagen stimulators and their use in the treatment of skin | |
| IT201600111171A1 (en) | KIT FOR SKIN TREATMENT AND ITS USE | |
| CN104586656A (en) | Hand cream | |
| CN111067860A (en) | Stem cell secretion factor mask for whitening skin and fading acne marks and preparation method thereof | |
| JP5291365B2 (en) | Keratin condition improving agent | |
| FR3004347A1 (en) | COSMETIC COMPOSITION COMPRISING ESSENTIAL OIL OF SAGE AND USE THEREOF | |
| JP7289833B2 (en) | Cosmetic use of plant Elephant extract (Phytelephas sp.) | |
| CN107854344A (en) | A kind of Essence and preparation method thereof | |
| CN105326659A (en) | Skin-whitening anti-wrinkle essence | |
| CN103222946B (en) | Preparation method for instantaneous penetration skin regeneration water composition containing American elderberry extract, guava extract and hydrolyzed pearl |